Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosravuconazole - Seren Pharmaceuticals

Next Previous
Drug Profile

Fosravuconazole - Seren Pharmaceuticals

Alternative Names: BFE-1224; BMS-379224; E-1224; Fosravuconazole L-lysine ethanolate; NAILIN; Ravuconazole prodrug - Eisai

Latest Information Update: 03 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Drugs for Neglected Diseases Initiative Foundation; Eisai Co Ltd; Seren Pharmaceuticals
  • Class Antifungals; Antiprotozoals; Benzonitrile; Fluorobenzenes; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis
  • Phase II/III Dermatomycoses
  • Phase II Chagas disease
  • Discontinued Mycoses

Most Recent Events

  • 03 Dec 2024 Eisai announces intention to submit the regulatory application to the National Medicines and Poisons Board in Sudan for Dermatomycoses (prior to December 2024) (Eisai Pipeline, December 2024)
  • 30 Mar 2023 Eisai in collaboration with DNDi and the University of Khartoum completes a phase II trial in Dermatomycoses in Sudan, before March 2023 (NCT03086226)
  • 14 Nov 2022 Phase-II/III clinical trials in Dermatomycoses in Sudan (PO) (Eisai pipeline, November 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top